A study has discovered that giving early breast cancer patients’ palbociclib alongside hormone treatment stopped tumor growth entirely.
Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
A report from the Institute of Cancer Research has found that cancer patients are waiting longer than ever for access to innovative drug treatments.
Erickson and colleagues evaluated hydration requirements with emetogenic chemotherapy and investigated the effects of an antiemetic drug combination.
Authors discuss the results of this observational real-world study and how sequencing tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.